Difference between revisions of "Stem cell mobilization regimens"
Warner-admin (talk | contribs) m (Text replacement - "756bb1" to "4a1486") |
Warner-admin (talk | contribs) m (Text replacement - "http://www.bloodjournal.org/content/115/6/1113" to "https://doi.org/10.1182/blood-2009-05-222539") |
||
(123 intermediate revisions by 4 users not shown) | |||
Line 1: | Line 1: | ||
− | + | <span id="BackToTop"></span> | |
− | + | <div class="noprint" style="background-color:LightGray; position:fixed; bottom:2%; right:0.25%; padding-left:5px; padding-right:5px; margin: 15px; opacity:0.8; border-style: solid; border-color:DarkGray; border-width: 1px"> | |
− | + | [[#top|Back to Top]] | |
− | + | </div> | |
− | + | {{#lst:Editorial board transclusions|transplant}} | |
− | + | Unlike the other chemotherapy regimen pages, this one is not disease-specific. Rather, this is meant to be a gathering point for all stem cell mobilization regimens. | |
− | |||
− | |||
− | |||
− | |} | ||
− | Unlike the other chemotherapy regimen pages, this one is not disease-specific. Rather, this is meant to be a gathering point for all stem cell mobilization | ||
− | |||
{| class="wikitable" style="float:right; margin-right: 5px;" | {| class="wikitable" style="float:right; margin-right: 5px;" | ||
|- | |- | ||
− | |<div style="background-color: #fee0d1; border: 1px solid #808000; padding: 5px; {{border-radius|16px}}" align="right"><font size="4"><b>{{#ask: [[-Has subobject::{{FULLPAGENAME}}]] |?Regimen |limit=10000|format=sum}} regimens on this page</b></font></div> | + | |<div style="background-color: #fee0d1; border: 1px solid #808000; padding: 5px; {{border-radius|16px}}" align="right"><font size="4"><b>{{#ask: [[-Has subobject::{{FULLPAGENAME}}]] |?Regimen |limit=10000|format=sum}} [[Tutorial#Regimens|regimens]] on this page</b></font></div> |
− | <div style="background-color: #deebf6; border: 1px solid #808000; padding: 5px; {{border-radius|16px}}"><font size="4"><b>{{#ask: [[-Has subobject::{{FULLPAGENAME}}]] |?Variant |limit=10000|format=sum}} variants on this page</b></font></div> | + | <div style="background-color: #deebf6; border: 1px solid #808000; padding: 5px; {{border-radius|16px}}"><font size="4"><b>{{#ask: [[-Has subobject::{{FULLPAGENAME}}]] |?Variant |limit=10000|format=sum}} [[Tutorial#Variants|variants]] on this page</b></font></div> |
|} | |} | ||
{{TOC limit|limit=3}} | {{TOC limit|limit=3}} | ||
− | + | =Stem cell mobilization, all lines of therapy= | |
− | =Stem cell mobilization= | ||
''These are regimens intended to mobilize stem cells, very incomplete right now but will be filled in over time.'' | ''These are regimens intended to mobilize stem cells, very incomplete right now but will be filled in over time.'' | ||
+ | ==CAD & G-CSF {{#subobject:b3c37f|Regimen=1}}== | ||
+ | CAD: '''<u>C</u>'''yclophosphamide, '''<u>A</u>'''driamycin (Doxorubicin), '''<u>D</u>'''examethasone | ||
+ | <div class="toccolours" style="background-color:#eeeeee"> | ||
+ | ===Regimen {{#subobject:0e8781|Variant=1}}=== | ||
+ | {| class="wikitable sortable" style="width: 60%; text-align:center;" | ||
+ | !style="width: 33%"|Study | ||
+ | !style="width: 33%"|Dates of enrollment | ||
+ | !style="width: 33%"|[[Levels_of_Evidence#Evidence|Evidence]] | ||
+ | |- | ||
+ | |[https://doi.org/10.1182/blood-2009-05-222539 Lokhorst et al. 2009 (HOVON-50)] | ||
+ | |2001-2005 | ||
+ | |style="background-color:#91cf61"|Non-randomized part of phase 3 RCT | ||
+ | |- | ||
+ | |} | ||
+ | ''This is reported as a stem cell mobilization regimen but presumably has anti-myeloma activity.'' | ||
+ | <div class="toccolours" style="background-color:#cbd5e8"> | ||
+ | ====Preceding treatment==== | ||
+ | *[[Multiple_myeloma,_induction#TAD_.28Thalidomide.29|TAD]] versus [[Multiple_myeloma_-_historical#VAD|VAD]] induction | ||
+ | </div> | ||
+ | <div class="toccolours" style="background-color:#b3e2cd"> | ||
+ | ====Chemotherapy==== | ||
+ | *[[Cyclophosphamide (Cytoxan)]] 1000 mg/m<sup>2</sup> IV once on day 1 | ||
+ | *[[Doxorubicin (Adriamycin)]] 15 mg/m<sup>2</sup> IV once per day on days 1 to 4 | ||
+ | ====Glucocorticoid therapy==== | ||
+ | *[[Dexamethasone (Decadron)]] 40 mg PO once per day on days 1 to 4 | ||
+ | ====Growth factor therapy==== | ||
+ | *[[Filgrastim (Neupogen)]] 5 mcg/kg SC twice per day until collection completed | ||
+ | '''One course''' | ||
+ | </div> | ||
+ | <div class="toccolours" style="background-color:#cbd5e7"> | ||
+ | ====Subsequent treatment==== | ||
+ | *[[Multiple_myeloma,_consolidation_and_maintenance#Melphalan_monotherapy.2C_then_auto_HSCT|High-dose melphalan, then auto HSCT]] or [[Multiple_myeloma,_consolidation_and_maintenance#Tandem_melphalan.2C_then_auto_HSCT|tandem high-dose melphalan, then auto HSCT]] consolidation (this was not a randomization but was pre-determined by the treating center) | ||
+ | </div></div> | ||
+ | ===References=== | ||
+ | # '''HOVON-50:''' Lokhorst HM, van der Holt B, Zweegman S, Vellenga E, Croockewit S, van Oers MH, von dem Borne P, Wijermans P, Schaafsma R, de Weerdt O, Wittebol S, Delforge M, Berenschot H, Bos GM, Jie KS, Sinnige H, van Marwijk-Kooy M, Joosten P, Minnema MC, van Ammerlaan R, Sonneveld P; Dutch-Belgian Hemato-Oncology Group (HOVON). A randomized phase 3 study on the effect of thalidomide combined with adriamycin, dexamethasone, and high-dose melphalan, followed by thalidomide maintenance in patients with multiple myeloma. Blood. 2010 Feb 11;115(6):1113-20. Epub 2009 Oct 30. [https://doi.org/10.1182/blood-2009-05-222539 link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/19880501/ PubMed] [https://clinicaltrials.gov/study/NCT00028886 NCT00028886] | ||
+ | ## '''Update:''' van de Donk NW, van der Holt B, Minnema MC, Vellenga E, Croockewit S, Kersten MJ, von dem Borne PA, Ypma P, Schaafsma R, de Weerdt O, Klein SK, Delforge M, Levin MD, Bos GM, Jie KG, Sinnige H, Coenen JL, de Waal EG, Zweegman S, Sonneveld P, Lokhorst HM. Thalidomide before and after autologous stem cell transplantation in recently diagnosed multiple myeloma (HOVON-50): long-term results from the phase 3, randomised controlled trial. Lancet Haematol. 2018 Oct;5(10):e479-e492. [https://doi.org/10.1016/S2352-3026(18)30149-2 link to original article] [https://pubmed.ncbi.nlm.nih.gov/30290905/ PubMed] | ||
==Cyclophosphamide & G-CSF {{#subobject:ebc1f1|Regimen=1}}== | ==Cyclophosphamide & G-CSF {{#subobject:ebc1f1|Regimen=1}}== | ||
− | + | <div class="toccolours" style="background-color:#eeeeee"> | |
− | + | ===Regimen variant #1 {{#subobject:f033a9|Variant=1}}=== | |
− | + | {| class="wikitable sortable" style="width: 60%; text-align:center;" | |
− | + | !style="width: 33%"|Study | |
− | ===Regimen #1 {{#subobject:f033a9|Variant=1}}=== | + | !style="width: 33%"|Dates of enrollment |
− | {| class="wikitable" style="width: | + | !style="width: 33%"|[[Levels_of_Evidence#Evidence|Evidence]] |
− | !Study | ||
− | ![[Levels_of_Evidence#Evidence|Evidence]] | ||
|- | |- | ||
− | |[ | + | |[https://doi.org/10.1111/j.1365-2141.2005.05519.x Oakervee et al. 2005] |
− | |style="background-color:#91cf61"|Phase | + | |NR |
+ | |style="background-color:#91cf61"|Phase 2 | ||
|- | |- | ||
|} | |} | ||
+ | <div class="toccolours" style="background-color:#b3e2cd"> | ||
====Chemotherapy==== | ====Chemotherapy==== | ||
*[[Cyclophosphamide (Cytoxan)]] 1500 mg/m<sup>2</sup> IV once on day 1 | *[[Cyclophosphamide (Cytoxan)]] 1500 mg/m<sup>2</sup> IV once on day 1 | ||
====Growth factor therapy==== | ====Growth factor therapy==== | ||
− | *[[Lenograstim (Granocyte)]] 263 mcg SC once per day starting on day 4 | + | *[[Lenograstim (Granocyte)]] 263 mcg SC once per day, starting on day 4 |
− | + | '''Stem cell collection begins on day 10 and continues until at least 2 x 10<sup>6</sup> CD34+ cells/kg are collected.''' | |
− | '''Stem cell collection begins on day 10 and continues until at least 2 | + | </div></div><br> |
− | + | <div class="toccolours" style="background-color:#eeeeee"> | |
− | ===Regimen #2 {{#subobject:0aa051|Variant=1}}=== | + | ===Regimen variant #2 {{#subobject:0aa051|Variant=1}}=== |
− | {| class="wikitable" style="width: | + | {| class="wikitable sortable" style="width: 60%; text-align:center;" |
− | !Study | + | !style="width: 33%"|Study |
− | ![[Levels_of_Evidence#Evidence|Evidence]] | + | !style="width: 33%"|Dates of enrollment |
+ | !style="width: 33%"|[[Levels_of_Evidence#Evidence|Evidence]] | ||
|- | |- | ||
− | |[ | + | |[https://doi.org/10.1200/jco.2015.63.1929 Royer et al. 2016] |
− | |style="background-color:#91cf61"|Phase | + | |2010-04 to 2013-07 |
+ | |style="background-color:#91cf61"|Phase 2 | ||
|- | |- | ||
|} | |} | ||
+ | <div class="toccolours" style="background-color:#b3e2cd"> | ||
====Chemotherapy==== | ====Chemotherapy==== | ||
*[[Cyclophosphamide (Cytoxan)]] 3000 mg/m<sup>2</sup> IV once | *[[Cyclophosphamide (Cytoxan)]] 3000 mg/m<sup>2</sup> IV once | ||
====Growth factor therapy==== | ====Growth factor therapy==== | ||
− | *[[Filgrastim (Neupogen)]] 10 mcg/kg SC once per day and continued until at least 4 | + | *[[Filgrastim (Neupogen)]] 10 mcg/kg SC once per day and continued until at least 4 x 10<sup>6</sup> CD34+ cells/kg are collected |
− | + | '''One course''' | |
+ | </div></div> | ||
===References=== | ===References=== | ||
− | # Oakervee HE, Popat R, Curry N, Smith P, Morris C, Drake M, Agrawal S, Stec J, Schenkein D, Esseltine DL, Cavenagh JD. PAD combination therapy (PS-341/bortezomib, doxorubicin and dexamethasone) for previously untreated patients with multiple myeloma. Br J Haematol. 2005 Jun;129(6):755-62. [ | + | # Oakervee HE, Popat R, Curry N, Smith P, Morris C, Drake M, Agrawal S, Stec J, Schenkein D, Esseltine DL, Cavenagh JD. PAD combination therapy (PS-341/bortezomib, doxorubicin and dexamethasone) for previously untreated patients with multiple myeloma. Br J Haematol. 2005 Jun;129(6):755-62. [https://doi.org/10.1111/j.1365-2141.2005.05519.x link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/15953001/ PubMed] |
− | + | # Royer B, Minvielle S, Diouf M, Roussel M, Karlin L, Hulin C, Arnulf B, Macro M, Cailleres S, Brion A, Brechignac S, Belhadj K, Chretien ML, Wetterwald M, Chaleteix C, Tiab M, Leleu X, Frenzel L, Garderet L, Choquet S, Fuzibet JG, Dauriac C, Forneker LM, Benboubker L, Facon T, Moreau P, Avet-Loiseau H, Marolleau JP; Intergroupe Francophone du Myélome. Bortezomib, Doxorubicin, Cyclophosphamide, Dexamethasone Induction Followed by Stem Cell Transplantation for Primary Plasma Cell Leukemia: A Prospective Phase II Study of the Intergroupe Francophone du Myélome. J Clin Oncol. 2016 Jun 20;34(18):2125-32. Epub 2016 Apr 25. [https://doi.org/10.1200/jco.2015.63.1929 link to original article] '''contains dosing details in abstract''' [https://pubmed.ncbi.nlm.nih.gov/27114594/ PubMed] EudraCT 2009-016607-33 | |
− | # Royer B, Minvielle S, Diouf M, Roussel M, Karlin L, Hulin C, Arnulf B, Macro M, Cailleres S, Brion A, Brechignac S, Belhadj K, Chretien ML, Wetterwald M, Chaleteix C, Tiab M, Leleu X, Frenzel L, Garderet L, Choquet S, Fuzibet JG, Dauriac C, Forneker LM, Benboubker L, Facon T, Moreau P, Avet-Loiseau H, Marolleau JP. Bortezomib, Doxorubicin, Cyclophosphamide, Dexamethasone Induction Followed by Stem Cell Transplantation for Primary Plasma Cell Leukemia: A Prospective Phase II Study of the Intergroupe Francophone du Myélome. J Clin Oncol. 2016 Jun 20;34(18):2125-32. Epub 2016 Apr 25. [ | ||
− | |||
==Cytarabine & G-CSF {{#subobject:ec0d95|Regimen=1}}== | ==Cytarabine & G-CSF {{#subobject:ec0d95|Regimen=1}}== | ||
− | {| class="wikitable" style=" | + | <div class="toccolours" style="background-color:#eeeeee"> |
+ | ===Regimen variant #1, 2000 mg/m<sup>2</sup> x 8 {{#subobject:36556f|Variant=1}}=== | ||
+ | {| class="wikitable" style="width: 40%; text-align:center;" | ||
+ | !style="width: 25%"|Study | ||
+ | !style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]] | ||
+ | |- | ||
+ | |[https://doi.org/10.1182/blood-2012-11-466862 Yanada et al. 2013 (JALSG APL205R)] | ||
+ | | style="background-color:#91cf61" |Phase 2 | ||
|- | |- | ||
− | |||
|} | |} | ||
− | + | ''Note: Target CD34+ cell dose: 2 x 10<sup>6</sup>/kg'' | |
− | ===Regimen {{#subobject:08473f|Variant=1}}=== | + | <div class="toccolours" style="background-color:#b3e2cd"> |
− | {| class="wikitable" style="width: | + | ====Chemotherapy==== |
− | !Study | + | *[[Cytarabine (Ara-C)]] 2000 mg/m<sup>2</sup> IV over 3 hours twice per day on days 1 to 4 (total dose: 16,000 mg/m<sup>2</sup>) |
− | ![[Levels_of_Evidence#Evidence|Evidence]] | + | ====Growth factor therapy==== |
+ | *[[Filgrastim (Neupogen)]] starting on day 6 (dose, frequency not specified) | ||
+ | '''One course''' | ||
+ | </div></div><br> | ||
+ | <div class="toccolours" style="background-color:#eeeeee"> | ||
+ | ===Regimen variant #2, 3000 mg/m<sup>2</sup> x 2 {{#subobject:08473f|Variant=1}}=== | ||
+ | {| class="wikitable sortable" style="width: 60%; text-align:center;" | ||
+ | !style="width: 33%"|Study | ||
+ | !style="width: 33%"|Dates of enrollment | ||
+ | !style="width: 33%"|[[Levels_of_Evidence#Evidence|Evidence]] | ||
|- | |- | ||
− | |[ | + | |[https://doi.org/10.1200/jco.2003.05.024 Abrey et al. 2003] |
− | |style="background-color:#91cf61"|Phase | + | |NR |
+ | |style="background-color:#91cf61"|Phase 2 | ||
|- | |- | ||
|} | |} | ||
+ | <div class="toccolours" style="background-color:#b3e2cd"> | ||
====Chemotherapy==== | ====Chemotherapy==== | ||
− | *[[Cytarabine ( | + | *[[Cytarabine (Ara-C)]] 3000 mg/m<sup>2</sup> IV once per day on days 1 & 2 |
====Growth factor therapy==== | ====Growth factor therapy==== | ||
− | *[[Filgrastim (Neupogen)]] 10 mcg/kg SC once per day starting on day 4 and continued until stem cell collection complete | + | *[[Filgrastim (Neupogen)]] 10 mcg/kg SC once per day, starting on day 4 and continued until stem cell collection complete |
− | + | '''One course''' | |
+ | </div></div> | ||
===References=== | ===References=== | ||
− | # Abrey LE, Moskowitz CH, Mason WP, Crump M, Stewart D, Forsyth P, Paleologos N, Correa DD, Anderson ND, Caron D, Zelenetz A, Nimer SD, DeAngelis LM. Intensive methotrexate and cytarabine followed by high-dose chemotherapy with autologous stem-cell rescue in patients with newly diagnosed primary CNS lymphoma: an intent-to-treat analysis. J Clin Oncol. 2003 Nov 15;21(22):4151-6. [ | + | # Abrey LE, Moskowitz CH, Mason WP, Crump M, Stewart D, Forsyth P, Paleologos N, Correa DD, Anderson ND, Caron D, Zelenetz A, Nimer SD, DeAngelis LM. Intensive methotrexate and cytarabine followed by high-dose chemotherapy with autologous stem-cell rescue in patients with newly diagnosed primary CNS lymphoma: an intent-to-treat analysis. J Clin Oncol. 2003 Nov 15;21(22):4151-6. [https://doi.org/10.1200/jco.2003.05.024 link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/14615443/ PubMed] |
+ | # '''JALSG APL205R:''' Yanada M, Tsuzuki M, Fujita H, Fujimaki K, Fujisawa S, Sunami K, Taniwaki M, Ohwada A, Tsuboi K, Maeda A, Takeshita A, Ohtake S, Miyazaki Y, Atsuta Y, Kobayashi Y, Naoe T, Emi N; Japan Adult Leukemia Study Group. Phase 2 study of arsenic trioxide followed by autologous hematopoietic cell transplantation for relapsed acute promyelocytic leukemia. Blood. 2013 Apr 18;121(16):3095-102. Epub 2013 Feb 14. [https://doi.org/10.1182/blood-2012-11-466862 link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/23412094/ PubMed] [https://clinicaltrials.gov/study/NCT01908621 NCT01908621] | ||
+ | # '''MMMobil-COI-01:''' Czerw T, Sadus-Wojciechowska M, Michalak K, Najda J, Mendrek W, Sobczyk-Kruszelnicka M, Glowala-Kosinska M, Chwieduk A, Mitrus I, Smagur A, Holowiecki J, Giebel S. Increased Efficacy of Stem Cell Chemomobilization with Intermediate-Dose Cytarabine Plus Granulocyte Colony-Stimulating Factor (G-CSF) Compared with G-CSF Alone in Patients with Multiple Myeloma: Results of a Randomized Trial. Biol Blood Marrow Transplant. 2019 Feb;25(2):248-255. Epub 2018 Sep 26. [https://www.bbmt.org/article/S1083-8791(18)30590-1 link to original article] [https://pubmed.ncbi.nlm.nih.gov/30266677/ PubMed] [https://clinicaltrials.gov/study/NCT01908621 NCT01908621] | ||
==Cytarabine, Ifosfamide, G-CSF {{#subobject:32fc16|Regimen=1}}== | ==Cytarabine, Ifosfamide, G-CSF {{#subobject:32fc16|Regimen=1}}== | ||
− | + | <div class="toccolours" style="background-color:#eeeeee"> | |
− | |||
− | |||
− | |||
− | |||
===Regimen {{#subobject:a8f29e|Variant=1}}=== | ===Regimen {{#subobject:a8f29e|Variant=1}}=== | ||
− | {| class="wikitable" style="width: | + | {| class="wikitable sortable" style="width: 60%; text-align:center;" |
− | !Study | + | !style="width: 33%"|Study |
− | ![[Levels_of_Evidence#Evidence|Evidence]] | + | !style="width: 33%"|Dates of enrollment |
+ | !style="width: 33%"|[[Levels_of_Evidence#Evidence|Evidence]] | ||
|- | |- | ||
− | |[ | + | |[https://doi.org/10.1038/sj.bmt.1705452 Colombat et al. 2006] |
− | |style="background-color:#91cf61"|Phase | + | |1999-2001 |
+ | |style="background-color:#91cf61"|Phase 2 | ||
|- | |- | ||
|} | |} | ||
+ | <div class="toccolours" style="background-color:#b3e2cd"> | ||
====Chemotherapy==== | ====Chemotherapy==== | ||
− | *[[Cytarabine ( | + | *[[Cytarabine (Ara-C)]] 1000 mg/m<sup>2</sup> IV every 12 hours on days 1 & 2 |
*[[Ifosfamide (Ifex)]] 1500 mg/m<sup>2</sup> IV once per day on days 1 to 3 | *[[Ifosfamide (Ifex)]] 1500 mg/m<sup>2</sup> IV once per day on days 1 to 3 | ||
====Growth factor therapy==== | ====Growth factor therapy==== | ||
*[[Filgrastim (Neupogen)]] (dose/frequency not specified) | *[[Filgrastim (Neupogen)]] (dose/frequency not specified) | ||
− | + | '''One course''' | |
+ | </div></div> | ||
===References=== | ===References=== | ||
− | # Colombat P, Lemevel A, Bertrand P, Delwail V, Rachieru P, Brion A, Berthou C, Bay JO, Delepine R, Desablens B, Camilleri-Broët S, Linassier C, Lamy T. High-dose chemotherapy with autologous stem cell transplantation as first-line therapy for primary CNS lymphoma in patients younger than 60 years: a multicenter phase II study of the GOELAMS group. Bone Marrow Transplant. 2006 Sep;38(6):417-20. [ | + | # Colombat P, Lemevel A, Bertrand P, Delwail V, Rachieru P, Brion A, Berthou C, Bay JO, Delepine R, Desablens B, Camilleri-Broët S, Linassier C, Lamy T. High-dose chemotherapy with autologous stem cell transplantation as first-line therapy for primary CNS lymphoma in patients younger than 60 years: a multicenter phase II study of the GOELAMS group. Bone Marrow Transplant. 2006 Sep;38(6):417-20. [https://doi.org/10.1038/sj.bmt.1705452 link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/16951691/ PubMed] |
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
+ | ==Cytarabine & Etoposide (CYVE) & G-CSF {{#subobject:a2d919|Regimen=1}}== | ||
+ | CYVE & G-CSF: '''<u>CY</u>'''tarabine, '''<u>VE</u>'''pesid (Etoposide), '''<u>G</u>'''ranulocyte '''<u>C</u>'''olony '''<u>S</u>'''timulating '''<u>F</u>'''actor | ||
+ | <div class="toccolours" style="background-color:#eeeeee"> | ||
===Regimen {{#subobject:b4b13a|Variant=1}}=== | ===Regimen {{#subobject:b4b13a|Variant=1}}=== | ||
− | {| class="wikitable" style="width: | + | {| class="wikitable sortable" style="width: 60%; text-align:center;" |
− | !Study | + | !style="width: 33%"|Study |
− | ![[Levels_of_Evidence#Evidence|Evidence]] | + | !style="width: 33%"|Dates of enrollment |
+ | !style="width: 33%"|[[Levels_of_Evidence#Evidence|Evidence]] | ||
|- | |- | ||
− | |[ | + | |[https://doi.org/10.1200/jco.2001.19.3.742 Soussain et al. 2001] |
+ | |1992-03 to 1995-03 | ||
|style="background-color:#91cf61"|Pilot, >20 pts | |style="background-color:#91cf61"|Pilot, >20 pts | ||
|- | |- | ||
− | |[ | + | |[https://doi.org/10.1200/jco.2007.13.5533 Soussain et al. 2008] |
− | |style="background-color:#91cf61"|Phase | + | |2000-01 to 2005-12 |
+ | |style="background-color:#91cf61"|Phase 2 | ||
|- | |- | ||
|} | |} | ||
− | ''Target collection dose not described; mobilization took place after the first course of [[CNS_lymphoma# | + | ''Note: Target collection dose not described; mobilization took place after the first course of [[CNS_lymphoma#Cytarabine_.26_Etoposide_.28CYVE.29|CYVE salvage for CNS lymphoma]].'' |
+ | <div class="toccolours" style="background-color:#b3e2cd"> | ||
====Chemotherapy==== | ====Chemotherapy==== | ||
− | *[[Cytarabine ( | + | *[[Cytarabine (Ara-C)]] 2000 mg/m<sup>2</sup> IV over 3 hours once per day on days 2 to 5 |
− | + | *[[Cytarabine (Ara-C)]] 50 mg/m<sup>2</sup> IV over 12 hours once per day on days 1 to 5 | |
− | * | ||
*[[Etoposide (Vepesid)]] 200 mg/m<sup>2</sup> IV over 2 hours once per day on days 2 to 5 | *[[Etoposide (Vepesid)]] 200 mg/m<sup>2</sup> IV over 2 hours once per day on days 2 to 5 | ||
====Growth factor therapy==== | ====Growth factor therapy==== | ||
− | *[[Filgrastim (Neupogen)]] 5 mcg/kg SC once per day starting 48 hours after end of chemotherapy | + | *[[Filgrastim (Neupogen)]] 5 mcg/kg SC once per day, starting 48 hours after end of chemotherapy |
− | + | '''One course''' | |
+ | </div></div> | ||
===References=== | ===References=== | ||
− | # Soussain C, Suzan F, Hoang-Xuan K, Cassoux N, Levy V, Azar N, Belanger C, Achour E, Ribrag V, Gerber S, Delattre JY, Leblond V. Results of intensive chemotherapy followed by hematopoietic stem-cell rescue in 22 patients with refractory or recurrent primary CNS lymphoma or intraocular lymphoma. J Clin Oncol. 2001 Feb 1;19(3):742-9. [ | + | # Soussain C, Suzan F, Hoang-Xuan K, Cassoux N, Levy V, Azar N, Belanger C, Achour E, Ribrag V, Gerber S, Delattre JY, Leblond V. Results of intensive chemotherapy followed by hematopoietic stem-cell rescue in 22 patients with refractory or recurrent primary CNS lymphoma or intraocular lymphoma. J Clin Oncol. 2001 Feb 1;19(3):742-9. [https://doi.org/10.1200/jco.2001.19.3.742 link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/11157026/ PubMed] |
− | # Soussain C, Hoang-Xuan K, Taillandier L, Fourme E, Choquet S, Witz F, Casasnovas O, Dupriez B, Souleau B, Taksin AL, Gisselbrecht C, Jaccard A, Omuro A, Sanson M, Janvier M, Kolb B, Zini JM, Leblond V; Société Française de Greffe de Moëlle Osseuse-Thérapie Cellulaire. Intensive chemotherapy followed by hematopoietic stem-cell rescue for refractory and recurrent primary CNS and intraocular lymphoma: Société Française de Greffe de Moëlle Osseuse-Thérapie Cellulaire. J Clin Oncol. 2008 May 20;26(15):2512-8. Epub 2008 Apr 14. [ | + | # Soussain C, Hoang-Xuan K, Taillandier L, Fourme E, Choquet S, Witz F, Casasnovas O, Dupriez B, Souleau B, Taksin AL, Gisselbrecht C, Jaccard A, Omuro A, Sanson M, Janvier M, Kolb B, Zini JM, Leblond V; Société Française de Greffe de Moëlle Osseuse-Thérapie Cellulaire. Intensive chemotherapy followed by hematopoietic stem-cell rescue for refractory and recurrent primary CNS and intraocular lymphoma: Société Française de Greffe de Moëlle Osseuse-Thérapie Cellulaire. J Clin Oncol. 2008 May 20;26(15):2512-8. Epub 2008 Apr 14. [https://doi.org/10.1200/jco.2007.13.5533 link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/18413641/ PubMed] |
− | + | ==DCEP & G-CSF {{#subobject:6e3266|Regimen=1}}== | |
− | == | + | DCEP & G-CSF: '''<u>D</u>'''examethasone, '''<u>C</u>'''yclophosphamide, '''<u>E</u>'''toposide, '''<u>P</u>'''latinol (Cisplatin), '''<u>G</u>'''ranulocyte '''<u>C</u>'''olony '''<u>S</u>'''timulating '''<u>F</u>'''actor |
− | {| class="wikitable" style=" | + | <div class="toccolours" style="background-color:#eeeeee"> |
+ | ===Regimen {{#subobject:8d0e51|Variant=1}}=== | ||
+ | {| class="wikitable sortable" style="width: 60%; text-align:center;" | ||
+ | !style="width: 33%"|Study | ||
+ | !style="width: 33%"|Dates of enrollment | ||
+ | !style="width: 33%"|[[Levels_of_Evidence#Evidence|Evidence]] | ||
+ | |- | ||
+ | |[http://www.haematologica.org/content/89/9/1124.long Corso et al. 2004] | ||
+ | |1996-2002 | ||
+ | |style="background-color:#91cf61"|Phase 2 | ||
|- | |- | ||
− | |||
|} | |} | ||
− | EAR: '''<u>E</u>'''toposide, '''<u>A</u>'''ra-C (Cytarabine), '''<u>R</u>'''ituximab '' | + | ''Note: Stem cells are mobilized and collected after each course of therapy.'' |
+ | <div class="toccolours" style="background-color:#b3e2cd"> | ||
+ | ====Glucocorticoid therapy==== | ||
+ | *[[Dexamethasone (Decadron)]] 40 mg PO once per day on days 1 to 4 | ||
+ | ====Chemotherapy==== | ||
+ | *[[Cyclophosphamide (Cytoxan)]] 400 mg/m<sup>2</sup>/day IV continuous infusion over 96 hours, started on day 1 (total dose per cycle: 1600 mg/m<sup>2</sup>) | ||
+ | *[[Etoposide (Vepesid)]] 40 mg/m<sup>2</sup>/day IV continuous infusion over 96 hours, started on day 1 (total dose per cycle: 160 mg/m<sup>2</sup>) | ||
+ | *[[Cisplatin (Platinol)]] 10 mg/m<sup>2</sup>/day IV continuous infusion over 96 hours, started on day 1 (total dose per cycle: 40 mg/m<sup>2</sup>) | ||
+ | ====Supportive therapy==== | ||
+ | *[[Filgrastim (Neupogen)]] 5 mcg/kg SC once per day, starting 48 hours after chemotherapy and continuing through stem cell collection | ||
+ | '''2 cycles (length not specified)''' | ||
+ | </div></div> | ||
+ | ===References=== | ||
+ | # Corso A, Barbarano L, Zappasodi P, Cairoli R, Alessandrino EP, Mangiacavalli S, Ferrari D, Fava S, Fiumanò M, Frigerio G, Isa L, Luraschi A, Klersy C, De Paoli A, Vergani C, Banfi L, Perego D, Ucci G, Pinotti G, Savarè M, Uziel L, Vismara A, Morra E, Lazzarino M. The VAD-DCEP sequence is an effective pre-transplant therapy in untreated multiple myeloma. Haematologica. 2004 Sep;89(9):1124-7. [http://www.haematologica.org/content/89/9/1124.long link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/15377474/ PubMed] | ||
+ | ==EAR & G-CSF {{#subobject:358013|Regimen=1}}== | ||
+ | EAR & G-CSF: '''<u>E</u>'''toposide, '''<u>A</u>'''ra-C (Cytarabine), '''<u>R</u>'''ituximab, '''<u>G</u>'''ranulocyte '''<u>C</u>'''olony '''<u>S</u>'''timulating '''<u>F</u>'''actor | ||
+ | <div class="toccolours" style="background-color:#eeeeee"> | ||
===Regimen {{#subobject:e580e|Variant=1}}=== | ===Regimen {{#subobject:e580e|Variant=1}}=== | ||
− | {| class="wikitable" style="width: | + | {| class="wikitable sortable" style="width: 60%; text-align:center;" |
− | !Study | + | !style="width: 33%"|Study |
− | ![[Levels_of_Evidence#Evidence|Evidence]] | + | !style="width: 33%"|Dates of enrollment |
+ | !style="width: 33%"|[[Levels_of_Evidence#Evidence|Evidence]] | ||
|- | |- | ||
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2793032/ Damon et al. 2009 (CALGB 59909)] | |[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2793032/ Damon et al. 2009 (CALGB 59909)] | ||
− | |style="background-color:#91cf61"|Phase | + | |2001-2004 |
+ | |style="background-color:#91cf61"|Phase 2 | ||
|- | |- | ||
|} | |} | ||
''Note: Text specified that PJP prophylaxis started during mobilization --although table 1 did not list it-- to continue until 3 months after auto HSCT.'' | ''Note: Text specified that PJP prophylaxis started during mobilization --although table 1 did not list it-- to continue until 3 months after auto HSCT.'' | ||
+ | <div class="toccolours" style="background-color:#cbd5e8"> | ||
====Preceding treatment==== | ====Preceding treatment==== | ||
− | *[[Mantle_cell_lymphoma#R-M-CHOP|R-M-CHOP]] x 2 to 3 cycles | + | *[[Mantle_cell_lymphoma#R-M-CHOP|R-M-CHOP]] induction x 2 to 3 cycles |
− | + | </div> | |
+ | <div class="toccolours" style="background-color:#b3e2cd"> | ||
====Chemotherapy==== | ====Chemotherapy==== | ||
− | *[[Etoposide (Vepesid)]] 10 mg/kg/day IV continuous infusion over 96 hours on | + | *[[Etoposide (Vepesid)]] 10 mg/kg/day IV continuous infusion over 96 hours, started on day 1 (total dose: 40 mg/kg) |
− | *[[Cytarabine ( | + | *[[Cytarabine (Ara-C)]] 2000 mg/m<sup>2</sup> IV over 2 hours twice per day on days 1 to 4 (total dose: 16,000 mg/m<sup>2</sup>) |
+ | ====Targeted therapy==== | ||
*[[Rituximab (Rituxan)]] 375 mg/m<sup>2</sup> IV once per day on days 6 & 13 | *[[Rituximab (Rituxan)]] 375 mg/m<sup>2</sup> IV once per day on days 6 & 13 | ||
− | + | ====Supportive therapy==== | |
− | ====Supportive | + | *[[Filgrastim (Neupogen)]] 10 mcg/kg SC once per day, starting on day 14, to continue until peripheral blood stem cell collection is complete |
− | *[[Filgrastim (Neupogen)]] 10 mcg/kg SC once per day starting on day 14, to continue until peripheral blood stem cell collection is complete | + | *[[Levofloxacin (Levaquin)]] 500 mg PO once per day, starting on day 7, to continue until ANC greater than or equal to 500/μL |
− | *[[Levofloxacin (Levaquin)]] 500 mg PO once per day, starting on day 7, to continue until ANC greater than or equal to 500/ | + | *[[Fluconazole (Diflucan)]] 200 mg PO once per day, starting on day 6, to continue until ANC greater than or equal to 500/μL |
− | *[[Fluconazole (Diflucan)]] 200 mg PO once per day, starting on day 6, to continue until ANC greater than or equal to 500/ | + | *[[Acyclovir (Zovirax)]] 200 mg PO three times per day, starting on day 6, to continue until 1 year after auto HSCT |
− | *[[Acyclovir (Zovirax)]] 200 mg PO | + | *[[Trimethoprim-Sulfamethoxazole (Bactrim DS)]] prophylaxis |
− | *[[Trimethoprim | + | '''Daily leukapheresis to start when WBC count more than or equal to 5 x 10<sup>9</sup>/L''' |
− | + | '''One course''' | |
− | '''Daily leukapheresis to start when WBC count | + | </div> |
− | + | <div class="toccolours" style="background-color:#cbd5e7"> | |
− | '' | + | ====Subsequent treatment==== |
− | + | *CALGB 59909, patients with adequate collection and meeting criteria: [[Mantle_cell_lymphoma#CBV.2C_then_auto_HSCT|CBV with autologous HSCT]] consolidation | |
+ | </div></div> | ||
===References=== | ===References=== | ||
− | # Damon LE, Johnson JL, Niedzwiecki D, Cheson BD, Hurd DD, Bartlett NL, Lacasce AS, Blum KA, Byrd JC, Kelly M, Stock W, Linker CA, Canellos GP. Immunochemotherapy and autologous stem-cell transplantation for untreated patients with mantle-cell lymphoma: CALGB 59909. J Clin Oncol. 2009 Dec 20;27(36):6101-8. Epub 2009 Nov 16. [ | + | # '''CALGB 59909:''' Damon LE, Johnson JL, Niedzwiecki D, Cheson BD, Hurd DD, Bartlett NL, Lacasce AS, Blum KA, Byrd JC, Kelly M, Stock W, Linker CA, Canellos GP. Immunochemotherapy and autologous stem-cell transplantation for untreated patients with mantle-cell lymphoma: CALGB 59909. J Clin Oncol. 2009 Dec 20;27(36):6101-8. Epub 2009 Nov 16. [https://doi.org/10.1200/jco.2009.22.2554 link to original article] '''contains dosing details in abstract''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2793032/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/19917845/ PubMed] |
− | |||
==IGEV & G-CSF {{#subobject:b15f5c|Regimen=1}}== | ==IGEV & G-CSF {{#subobject:b15f5c|Regimen=1}}== | ||
− | + | IGEV & G-CSF: '''<u>I</u>'''fosfamide, '''<u>GE</u>'''mcitabine, '''<u>V</u>'''inorelbine, '''<u>G</u>'''ranulocyte '''<u>C</u>'''olony '''<u>S</u>'''timulating '''<u>F</u>'''actor | |
− | + | <div class="toccolours" style="background-color:#eeeeee"> | |
− | |||
− | |||
− | |||
===Regimen {{#subobject:116473|Variant=1}}=== | ===Regimen {{#subobject:116473|Variant=1}}=== | ||
− | {| class="wikitable" style="width: | + | {| class="wikitable sortable" style="width: 60%; text-align:center;" |
− | !Study | + | !style="width: 33%"|Study |
− | ![[Levels_of_Evidence#Evidence|Evidence]] | + | !style="width: 33%"|Dates of enrollment |
+ | !style="width: 33%"|[[Levels_of_Evidence#Evidence|Evidence]] | ||
|- | |- | ||
− | |[ | + | |[https://doi.org/10.1038/sj.bmt.1705862 Magagnoli et al. 2007] |
− | |style="background-color:#91cf61"|Phase | + | |1997-11 to 2006-07 |
+ | |style="background-color:#91cf61"|Phase 2 | ||
|- | |- | ||
|} | |} | ||
+ | <div class="toccolours" style="background-color:#b3e2cd"> | ||
====Chemotherapy==== | ====Chemotherapy==== | ||
*[[Ifosfamide (Ifex)]] 2000 mg/m<sup>2</sup> IV over 2 hours once per day on days 1 to 4 | *[[Ifosfamide (Ifex)]] 2000 mg/m<sup>2</sup> IV over 2 hours once per day on days 1 to 4 | ||
*[[Gemcitabine (Gemzar)]] 800 mg/m<sup>2</sup> IV once per day on days 1 & 4 | *[[Gemcitabine (Gemzar)]] 800 mg/m<sup>2</sup> IV once per day on days 1 & 4 | ||
*[[Vinorelbine (Navelbine)]] 20 mg/m<sup>2</sup> IV once on day 1 | *[[Vinorelbine (Navelbine)]] 20 mg/m<sup>2</sup> IV once on day 1 | ||
+ | ====Glucocorticoid therapy==== | ||
*[[Prednisolone (Millipred)]] 100 mg PO once per day on days 1 to 4 | *[[Prednisolone (Millipred)]] 100 mg PO once per day on days 1 to 4 | ||
− | + | ====Supportive therapy==== | |
− | ====Supportive | + | *[[Mesna (Mesnex)]] 900 mg/m<sup>2</sup> IV three times per day on days 1 to 4, '''given at 0, 2, 4 hours after ifosfamide''' (total dose: 10,800 mg/m<sup>2</sup>) |
− | *[[Mesna (Mesnex)]] 900 mg/m<sup>2</sup> IV at 0, 2, 4 hours after | ||
*[[Lenograstim (Granocyte)]] 263 mcg SC once per day on days 7 until at least 3 x 10<sup>6</sup> CD34+ cells per kg of body weight were collected | *[[Lenograstim (Granocyte)]] 263 mcg SC once per day on days 7 until at least 3 x 10<sup>6</sup> CD34+ cells per kg of body weight were collected | ||
− | |||
'''Apheresis was performed when the peripheral blood CD34+ cell count exceeded 10 cells/ul.''' | '''Apheresis was performed when the peripheral blood CD34+ cell count exceeded 10 cells/ul.''' | ||
− | + | '''One course''' | |
+ | </div></div> | ||
===References=== | ===References=== | ||
− | # Magagnoli M, Spina M, Balzarotti M, Timofeeva I, Isa L, Michieli M, Capizzuto R, Morenghi E, Castagna L, Tirelli U, Santoro A. IGEV regimen and a fixed dose of lenograstim: an effective mobilization regimen in pretreated Hodgkin's lymphoma patients. Bone Marrow Transplant. 2007 Dec;40(11):1019-25. Epub 2007 Oct 1. [ | + | # Magagnoli M, Spina M, Balzarotti M, Timofeeva I, Isa L, Michieli M, Capizzuto R, Morenghi E, Castagna L, Tirelli U, Santoro A. IGEV regimen and a fixed dose of lenograstim: an effective mobilization regimen in pretreated Hodgkin's lymphoma patients. Bone Marrow Transplant. 2007 Dec;40(11):1019-25. Epub 2007 Oct 1. [https://doi.org/10.1038/sj.bmt.1705862 link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/17906705/ PubMed] |
− | |||
==DexaBEAM & G-CSF {{#subobject:542726|Regimen=1}}== | ==DexaBEAM & G-CSF {{#subobject:542726|Regimen=1}}== | ||
− | + | DexaBEAM & G-CSF: '''<u>Dexa</u>'''methasone, '''<u>B</u>'''iCNU (Carmustine), '''<u>E</u>'''toposide, '''<u>A</u>'''ra-C (Cytarabine), '''<u>M</u>'''elphalan, '''<u>G</u>'''ranulocyte '''<u>C</u>'''olony '''<u>S</u>'''timulating '''<u>F</u>'''actor | |
− | + | <div class="toccolours" style="background-color:#eeeeee"> | |
− | |||
− | |||
− | |||
===Regimen {{#subobject:41ae94|Variant=1}}=== | ===Regimen {{#subobject:41ae94|Variant=1}}=== | ||
− | {| class="wikitable" style="width: | + | {| class="wikitable sortable" style="width: 60%; text-align:center;" |
− | !Study | + | !style="width: 33%"|Study |
− | ![[Levels_of_Evidence#Evidence|Evidence]] | + | !style="width: 33%"|Dates of enrollment |
+ | !style="width: 33%"|[[Levels_of_Evidence#Evidence|Evidence]] | ||
|- | |- | ||
− | |[ | + | |[https://doi.org/10.1182/blood-2004-10-3883 Dreyling et al. 2004] |
− | | style="background-color:#91cf61" |Non-randomized | + | |1996-2004 |
+ | | style="background-color:#91cf61" |Non-randomized part of phase 3 RCT | ||
|- | |- | ||
|} | |} | ||
+ | <div class="toccolours" style="background-color:#b3e2cd"> | ||
+ | ====Glucocorticoid therapy==== | ||
+ | *[[Dexamethasone (Decadron)]] 8 mg PO three times per day on days 1 to 10 | ||
====Chemotherapy==== | ====Chemotherapy==== | ||
− | + | *[[Carmustine (BCNU)]] 60 mg/m<sup>2</sup> IV once on day 2 | |
− | *[[Carmustine ( | ||
*[[Etoposide (Vepesid)]] 75 mg/m<sup>2</sup> IV once per day on days 4 to 7 | *[[Etoposide (Vepesid)]] 75 mg/m<sup>2</sup> IV once per day on days 4 to 7 | ||
− | *[[Cytarabine ( | + | *[[Cytarabine (Ara-C)]] 100 mg/m<sup>2</sup> IV twice per day on days 4 to 7 |
*[[Melphalan (Alkeran)]] 20 mg/m<sup>2</sup> IV once on day 3 | *[[Melphalan (Alkeran)]] 20 mg/m<sup>2</sup> IV once on day 3 | ||
− | |||
====Growth factor therapy==== | ====Growth factor therapy==== | ||
*[[:Category:Granulocyte_colony-stimulating_factors|G-CSF]] starting on day 11 | *[[:Category:Granulocyte_colony-stimulating_factors|G-CSF]] starting on day 11 | ||
+ | ''A minimum of 1 x 10<sup>6</sup> CD34+ cells/kg are collected.'' | ||
+ | '''One course''' | ||
+ | </div></div> | ||
+ | ===References=== | ||
+ | # Dreyling M, Lenz G, Hoster E, Van Hoof A, Gisselbrecht C, Schmits R, Metzner B, Truemper L, Reiser M, Steinhauer H, Boiron JM, Boogaerts MA, Aldaoud A, Silingardi V, Kluin-Nelemans HC, Hasford J, Parwaresch R, Unterhalt M, Hiddemann W. Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the European MCL Network. Blood. 2005 Apr 1;105(7):2677-84. Epub 2004 Dec 9. [https://doi.org/10.1182/blood-2004-10-3883 link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/15591112/ PubMed] | ||
− | '' | + | ==Motixafortide & G-CSF {{#subobject:87ojnc|Regimen=1}}== |
+ | <div class="toccolours" style="background-color:#eeeeee"> | ||
+ | ===Regimen {{#subobject:36uhcb|Variant=1}}=== | ||
+ | {| class="wikitable sortable" style="width: 100%; text-align:center;" | ||
+ | !style="width: 20%"|Study | ||
+ | !style="width: 20%"|Dates of enrollment | ||
+ | !style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]] | ||
+ | !style="width: 20%"|Comparator | ||
+ | !style="width: 20%"|[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]] | ||
+ | |- | ||
+ | |[https://www.ncbi.nlm.nih.gov/pmc/articles/pmc10115633/ Crees et al. 2023 (GENESIS)] | ||
+ | |2018-01-22 to 2020-10-30 | ||
+ | | style="background-color:#1a9851" |Phase 3 (E-RT-esc) | ||
+ | |[[#G-CSF_monotherapy|G-CSF]] | ||
+ | | style="background-color:#1a9850" |Superior primary endpoint | ||
+ | |- | ||
+ | |} | ||
+ | <div class="toccolours" style="background-color:#b3e2cd"> | ||
+ | ====Growth factor therapy==== | ||
+ | *[[Motixafortide (Aphexda)]] | ||
+ | *[[:Category:Granulocyte_colony-stimulating_factors|G-CSF]] | ||
+ | '''One course''' | ||
+ | </div></div> | ||
+ | ===References=== | ||
+ | #'''GENESIS:''' Crees ZD, Rettig MP, Jayasinghe RG, Stockerl-Goldstein K, Larson SM, Arpad I, Milone GA, Martino M, Stiff P, Sborov D, Pereira D, Micallef I, Moreno-Jiménez G, Mikala G, Coronel MLP, Holtick U, Hiemenz J, Qazilbash MH, Hardy N, Latif T, García-Cadenas I, Vainstein-Haras A, Sorani E, Gliko-Kabir I, Goldstein I, Ickowicz D, Shemesh-Darvish L, Kadosh S, Gao F, Schroeder MA, Vij R, DiPersio JF. Motixafortide and G-CSF to mobilize hematopoietic stem cells for autologous transplantation in multiple myeloma: a randomized phase 3 trial. Nat Med. 2023 Apr;29(4):869-879. Epub 2023 Apr 17. [https://doi.org/10.1038/s41591-023-02273-z link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc10115633/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/37069359/ PubMed] [https://clinicaltrials.gov/study/NCT03246529 NCT03246529] | ||
+ | ==Plerixafor & G-CSF {{#subobject:87yb26|Regimen=1}}== | ||
+ | <div class="toccolours" style="background-color:#eeeeee"> | ||
+ | ===Regimen {{#subobject:36hz94|Variant=1}}=== | ||
+ | {| class="wikitable sortable" style="width: 100%; text-align:center;" | ||
+ | !style="width: 20%"|Study | ||
+ | !style="width: 20%"|Dates of enrollment | ||
+ | !style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]] | ||
+ | !style="width: 20%"|Comparator | ||
+ | !style="width: 20%"|[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]] | ||
+ | |- | ||
+ | |[https://doi.org/10.1200/JCO.2008.20.7209 DiPersio et al. 2009 (Study 3101)] | ||
+ | |2005-01-18 to 2006-08-20 | ||
+ | | style="background-color:#1a9851" |Phase 3 (E-esc) | ||
+ | |[[#G-CSF_monotherapy|G-CSF]] | ||
+ | | style="background-color:#1a9850" |Superior primary endpoint | ||
+ | |- | ||
+ | |[https://doi.org/10.1182/blood-2008-08-174946 DiPersio et al. 2009 (AMD3100-3102)] | ||
+ | |2005-02-04 to 2006-07-07 | ||
+ | | style="background-color:#1a9851" |Phase 3 (E-esc) | ||
+ | |[[#G-CSF_monotherapy|G-CSF]] | ||
+ | | style="background-color:#1a9850" |Superior primary endpoint | ||
+ | |- | ||
+ | |} | ||
+ | <div class="toccolours" style="background-color:#b3e2cd"> | ||
+ | ====Growth factor therapy==== | ||
+ | *[[Plerixafor (Mozobil)]] | ||
+ | *[[:Category:Granulocyte_colony-stimulating_factors|G-CSF]] | ||
+ | '''One course''' | ||
+ | </div></div> | ||
===References=== | ===References=== | ||
− | # | + | # '''AMD3100-3102:''' DiPersio JF, Stadtmauer EA, Nademanee A, Micallef IN, Stiff PJ, Kaufman JL, Maziarz RT, Hosing C, Früehauf S, Horwitz M, Cooper D, Bridger G, Calandra G; 3102 Investigators. Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma. Blood. 2009 Jun 4;113(23):5720-6. Epub 2009 Apr 10. [https://doi.org/10.1182/blood-2008-08-174946 link to original article] [https://pubmed.ncbi.nlm.nih.gov/19363221/ PubMed] [https://clinicaltrials.gov/study/NCT00103662 NCT00103662] |
+ | # '''Study 3101:''' DiPersio JF, Micallef IN, Stiff PJ, Bolwell BJ, Maziarz RT, Jacobsen E, Nademanee A, McCarty J, Bridger G, Calandra G; 3101 Investigators. Phase III prospective randomized double-blind placebo-controlled trial of plerixafor plus granulocyte colony-stimulating factor compared with placebo plus granulocyte colony-stimulating factor for autologous stem-cell mobilization and transplantation for patients with non-Hodgkin's lymphoma. J Clin Oncol. 2009 Oct 1;27(28):4767-73. Epub 2009 Aug 31. [https://doi.org/10.1200/JCO.2008.20.7209 link to original article] [https://pubmed.ncbi.nlm.nih.gov/19720922/ PubMed] [https://clinicaltrials.gov/study/NCT00103610 NCT00103610] | ||
[[Category:Stem cell mobilization regimens]] | [[Category:Stem cell mobilization regimens]] | ||
− | [[Category: | + | [[Category:Site-agnostic regimens]] |
Revision as of 12:19, 26 June 2024
Section editor | |
---|---|
Talal Hilal, MD Mayo Clinic Phoenix, AZ, USA |
Unlike the other chemotherapy regimen pages, this one is not disease-specific. Rather, this is meant to be a gathering point for all stem cell mobilization regimens.
11 regimens on this page
13 variants on this page
|
Stem cell mobilization, all lines of therapy
These are regimens intended to mobilize stem cells, very incomplete right now but will be filled in over time.
CAD & G-CSF
CAD: Cyclophosphamide, Adriamycin (Doxorubicin), Dexamethasone
Regimen
Study | Dates of enrollment | Evidence |
---|---|---|
Lokhorst et al. 2009 (HOVON-50) | 2001-2005 | Non-randomized part of phase 3 RCT |
This is reported as a stem cell mobilization regimen but presumably has anti-myeloma activity.
Chemotherapy
- Cyclophosphamide (Cytoxan) 1000 mg/m2 IV once on day 1
- Doxorubicin (Adriamycin) 15 mg/m2 IV once per day on days 1 to 4
Glucocorticoid therapy
- Dexamethasone (Decadron) 40 mg PO once per day on days 1 to 4
Growth factor therapy
- Filgrastim (Neupogen) 5 mcg/kg SC twice per day until collection completed
One course
Subsequent treatment
- High-dose melphalan, then auto HSCT or tandem high-dose melphalan, then auto HSCT consolidation (this was not a randomization but was pre-determined by the treating center)
References
- HOVON-50: Lokhorst HM, van der Holt B, Zweegman S, Vellenga E, Croockewit S, van Oers MH, von dem Borne P, Wijermans P, Schaafsma R, de Weerdt O, Wittebol S, Delforge M, Berenschot H, Bos GM, Jie KS, Sinnige H, van Marwijk-Kooy M, Joosten P, Minnema MC, van Ammerlaan R, Sonneveld P; Dutch-Belgian Hemato-Oncology Group (HOVON). A randomized phase 3 study on the effect of thalidomide combined with adriamycin, dexamethasone, and high-dose melphalan, followed by thalidomide maintenance in patients with multiple myeloma. Blood. 2010 Feb 11;115(6):1113-20. Epub 2009 Oct 30. link to original article contains dosing details in manuscript PubMed NCT00028886
- Update: van de Donk NW, van der Holt B, Minnema MC, Vellenga E, Croockewit S, Kersten MJ, von dem Borne PA, Ypma P, Schaafsma R, de Weerdt O, Klein SK, Delforge M, Levin MD, Bos GM, Jie KG, Sinnige H, Coenen JL, de Waal EG, Zweegman S, Sonneveld P, Lokhorst HM. Thalidomide before and after autologous stem cell transplantation in recently diagnosed multiple myeloma (HOVON-50): long-term results from the phase 3, randomised controlled trial. Lancet Haematol. 2018 Oct;5(10):e479-e492. link to original article PubMed
Cyclophosphamide & G-CSF
Regimen variant #1
Study | Dates of enrollment | Evidence |
---|---|---|
Oakervee et al. 2005 | NR | Phase 2 |
Chemotherapy
- Cyclophosphamide (Cytoxan) 1500 mg/m2 IV once on day 1
Growth factor therapy
- Lenograstim (Granocyte) 263 mcg SC once per day, starting on day 4
Stem cell collection begins on day 10 and continues until at least 2 x 106 CD34+ cells/kg are collected.
Regimen variant #2
Study | Dates of enrollment | Evidence |
---|---|---|
Royer et al. 2016 | 2010-04 to 2013-07 | Phase 2 |
Chemotherapy
- Cyclophosphamide (Cytoxan) 3000 mg/m2 IV once
Growth factor therapy
- Filgrastim (Neupogen) 10 mcg/kg SC once per day and continued until at least 4 x 106 CD34+ cells/kg are collected
One course
References
- Oakervee HE, Popat R, Curry N, Smith P, Morris C, Drake M, Agrawal S, Stec J, Schenkein D, Esseltine DL, Cavenagh JD. PAD combination therapy (PS-341/bortezomib, doxorubicin and dexamethasone) for previously untreated patients with multiple myeloma. Br J Haematol. 2005 Jun;129(6):755-62. link to original article contains dosing details in manuscript PubMed
- Royer B, Minvielle S, Diouf M, Roussel M, Karlin L, Hulin C, Arnulf B, Macro M, Cailleres S, Brion A, Brechignac S, Belhadj K, Chretien ML, Wetterwald M, Chaleteix C, Tiab M, Leleu X, Frenzel L, Garderet L, Choquet S, Fuzibet JG, Dauriac C, Forneker LM, Benboubker L, Facon T, Moreau P, Avet-Loiseau H, Marolleau JP; Intergroupe Francophone du Myélome. Bortezomib, Doxorubicin, Cyclophosphamide, Dexamethasone Induction Followed by Stem Cell Transplantation for Primary Plasma Cell Leukemia: A Prospective Phase II Study of the Intergroupe Francophone du Myélome. J Clin Oncol. 2016 Jun 20;34(18):2125-32. Epub 2016 Apr 25. link to original article contains dosing details in abstract PubMed EudraCT 2009-016607-33
Cytarabine & G-CSF
Regimen variant #1, 2000 mg/m2 x 8
Study | Evidence |
---|---|
Yanada et al. 2013 (JALSG APL205R) | Phase 2 |
Note: Target CD34+ cell dose: 2 x 106/kg
Chemotherapy
- Cytarabine (Ara-C) 2000 mg/m2 IV over 3 hours twice per day on days 1 to 4 (total dose: 16,000 mg/m2)
Growth factor therapy
- Filgrastim (Neupogen) starting on day 6 (dose, frequency not specified)
One course
Regimen variant #2, 3000 mg/m2 x 2
Study | Dates of enrollment | Evidence |
---|---|---|
Abrey et al. 2003 | NR | Phase 2 |
Chemotherapy
- Cytarabine (Ara-C) 3000 mg/m2 IV once per day on days 1 & 2
Growth factor therapy
- Filgrastim (Neupogen) 10 mcg/kg SC once per day, starting on day 4 and continued until stem cell collection complete
One course
References
- Abrey LE, Moskowitz CH, Mason WP, Crump M, Stewart D, Forsyth P, Paleologos N, Correa DD, Anderson ND, Caron D, Zelenetz A, Nimer SD, DeAngelis LM. Intensive methotrexate and cytarabine followed by high-dose chemotherapy with autologous stem-cell rescue in patients with newly diagnosed primary CNS lymphoma: an intent-to-treat analysis. J Clin Oncol. 2003 Nov 15;21(22):4151-6. link to original article contains dosing details in manuscript PubMed
- JALSG APL205R: Yanada M, Tsuzuki M, Fujita H, Fujimaki K, Fujisawa S, Sunami K, Taniwaki M, Ohwada A, Tsuboi K, Maeda A, Takeshita A, Ohtake S, Miyazaki Y, Atsuta Y, Kobayashi Y, Naoe T, Emi N; Japan Adult Leukemia Study Group. Phase 2 study of arsenic trioxide followed by autologous hematopoietic cell transplantation for relapsed acute promyelocytic leukemia. Blood. 2013 Apr 18;121(16):3095-102. Epub 2013 Feb 14. link to original article contains dosing details in manuscript PubMed NCT01908621
- MMMobil-COI-01: Czerw T, Sadus-Wojciechowska M, Michalak K, Najda J, Mendrek W, Sobczyk-Kruszelnicka M, Glowala-Kosinska M, Chwieduk A, Mitrus I, Smagur A, Holowiecki J, Giebel S. Increased Efficacy of Stem Cell Chemomobilization with Intermediate-Dose Cytarabine Plus Granulocyte Colony-Stimulating Factor (G-CSF) Compared with G-CSF Alone in Patients with Multiple Myeloma: Results of a Randomized Trial. Biol Blood Marrow Transplant. 2019 Feb;25(2):248-255. Epub 2018 Sep 26. link to original article PubMed NCT01908621
Cytarabine, Ifosfamide, G-CSF
Regimen
Study | Dates of enrollment | Evidence |
---|---|---|
Colombat et al. 2006 | 1999-2001 | Phase 2 |
Chemotherapy
- Cytarabine (Ara-C) 1000 mg/m2 IV every 12 hours on days 1 & 2
- Ifosfamide (Ifex) 1500 mg/m2 IV once per day on days 1 to 3
Growth factor therapy
- Filgrastim (Neupogen) (dose/frequency not specified)
One course
References
- Colombat P, Lemevel A, Bertrand P, Delwail V, Rachieru P, Brion A, Berthou C, Bay JO, Delepine R, Desablens B, Camilleri-Broët S, Linassier C, Lamy T. High-dose chemotherapy with autologous stem cell transplantation as first-line therapy for primary CNS lymphoma in patients younger than 60 years: a multicenter phase II study of the GOELAMS group. Bone Marrow Transplant. 2006 Sep;38(6):417-20. link to original article contains dosing details in manuscript PubMed
Cytarabine & Etoposide (CYVE) & G-CSF
CYVE & G-CSF: CYtarabine, VEpesid (Etoposide), Granulocyte Colony Stimulating Factor
Regimen
Study | Dates of enrollment | Evidence |
---|---|---|
Soussain et al. 2001 | 1992-03 to 1995-03 | Pilot, >20 pts |
Soussain et al. 2008 | 2000-01 to 2005-12 | Phase 2 |
Note: Target collection dose not described; mobilization took place after the first course of CYVE salvage for CNS lymphoma.
Chemotherapy
- Cytarabine (Ara-C) 2000 mg/m2 IV over 3 hours once per day on days 2 to 5
- Cytarabine (Ara-C) 50 mg/m2 IV over 12 hours once per day on days 1 to 5
- Etoposide (Vepesid) 200 mg/m2 IV over 2 hours once per day on days 2 to 5
Growth factor therapy
- Filgrastim (Neupogen) 5 mcg/kg SC once per day, starting 48 hours after end of chemotherapy
One course
References
- Soussain C, Suzan F, Hoang-Xuan K, Cassoux N, Levy V, Azar N, Belanger C, Achour E, Ribrag V, Gerber S, Delattre JY, Leblond V. Results of intensive chemotherapy followed by hematopoietic stem-cell rescue in 22 patients with refractory or recurrent primary CNS lymphoma or intraocular lymphoma. J Clin Oncol. 2001 Feb 1;19(3):742-9. link to original article contains dosing details in manuscript PubMed
- Soussain C, Hoang-Xuan K, Taillandier L, Fourme E, Choquet S, Witz F, Casasnovas O, Dupriez B, Souleau B, Taksin AL, Gisselbrecht C, Jaccard A, Omuro A, Sanson M, Janvier M, Kolb B, Zini JM, Leblond V; Société Française de Greffe de Moëlle Osseuse-Thérapie Cellulaire. Intensive chemotherapy followed by hematopoietic stem-cell rescue for refractory and recurrent primary CNS and intraocular lymphoma: Société Française de Greffe de Moëlle Osseuse-Thérapie Cellulaire. J Clin Oncol. 2008 May 20;26(15):2512-8. Epub 2008 Apr 14. link to original article contains dosing details in manuscript PubMed
DCEP & G-CSF
DCEP & G-CSF: Dexamethasone, Cyclophosphamide, Etoposide, Platinol (Cisplatin), Granulocyte Colony Stimulating Factor
Regimen
Study | Dates of enrollment | Evidence |
---|---|---|
Corso et al. 2004 | 1996-2002 | Phase 2 |
Note: Stem cells are mobilized and collected after each course of therapy.
Glucocorticoid therapy
- Dexamethasone (Decadron) 40 mg PO once per day on days 1 to 4
Chemotherapy
- Cyclophosphamide (Cytoxan) 400 mg/m2/day IV continuous infusion over 96 hours, started on day 1 (total dose per cycle: 1600 mg/m2)
- Etoposide (Vepesid) 40 mg/m2/day IV continuous infusion over 96 hours, started on day 1 (total dose per cycle: 160 mg/m2)
- Cisplatin (Platinol) 10 mg/m2/day IV continuous infusion over 96 hours, started on day 1 (total dose per cycle: 40 mg/m2)
Supportive therapy
- Filgrastim (Neupogen) 5 mcg/kg SC once per day, starting 48 hours after chemotherapy and continuing through stem cell collection
2 cycles (length not specified)
References
- Corso A, Barbarano L, Zappasodi P, Cairoli R, Alessandrino EP, Mangiacavalli S, Ferrari D, Fava S, Fiumanò M, Frigerio G, Isa L, Luraschi A, Klersy C, De Paoli A, Vergani C, Banfi L, Perego D, Ucci G, Pinotti G, Savarè M, Uziel L, Vismara A, Morra E, Lazzarino M. The VAD-DCEP sequence is an effective pre-transplant therapy in untreated multiple myeloma. Haematologica. 2004 Sep;89(9):1124-7. link to original article contains dosing details in manuscript PubMed
EAR & G-CSF
EAR & G-CSF: Etoposide, Ara-C (Cytarabine), Rituximab, Granulocyte Colony Stimulating Factor
Regimen
Study | Dates of enrollment | Evidence |
---|---|---|
Damon et al. 2009 (CALGB 59909) | 2001-2004 | Phase 2 |
Note: Text specified that PJP prophylaxis started during mobilization --although table 1 did not list it-- to continue until 3 months after auto HSCT.
Preceding treatment
- R-M-CHOP induction x 2 to 3 cycles
Chemotherapy
- Etoposide (Vepesid) 10 mg/kg/day IV continuous infusion over 96 hours, started on day 1 (total dose: 40 mg/kg)
- Cytarabine (Ara-C) 2000 mg/m2 IV over 2 hours twice per day on days 1 to 4 (total dose: 16,000 mg/m2)
Targeted therapy
- Rituximab (Rituxan) 375 mg/m2 IV once per day on days 6 & 13
Supportive therapy
- Filgrastim (Neupogen) 10 mcg/kg SC once per day, starting on day 14, to continue until peripheral blood stem cell collection is complete
- Levofloxacin (Levaquin) 500 mg PO once per day, starting on day 7, to continue until ANC greater than or equal to 500/μL
- Fluconazole (Diflucan) 200 mg PO once per day, starting on day 6, to continue until ANC greater than or equal to 500/μL
- Acyclovir (Zovirax) 200 mg PO three times per day, starting on day 6, to continue until 1 year after auto HSCT
- Trimethoprim-Sulfamethoxazole (Bactrim DS) prophylaxis
Daily leukapheresis to start when WBC count more than or equal to 5 x 109/L One course
Subsequent treatment
- CALGB 59909, patients with adequate collection and meeting criteria: CBV with autologous HSCT consolidation
References
- CALGB 59909: Damon LE, Johnson JL, Niedzwiecki D, Cheson BD, Hurd DD, Bartlett NL, Lacasce AS, Blum KA, Byrd JC, Kelly M, Stock W, Linker CA, Canellos GP. Immunochemotherapy and autologous stem-cell transplantation for untreated patients with mantle-cell lymphoma: CALGB 59909. J Clin Oncol. 2009 Dec 20;27(36):6101-8. Epub 2009 Nov 16. link to original article contains dosing details in abstract link to PMC article PubMed
IGEV & G-CSF
IGEV & G-CSF: Ifosfamide, GEmcitabine, Vinorelbine, Granulocyte Colony Stimulating Factor
Regimen
Study | Dates of enrollment | Evidence |
---|---|---|
Magagnoli et al. 2007 | 1997-11 to 2006-07 | Phase 2 |
Chemotherapy
- Ifosfamide (Ifex) 2000 mg/m2 IV over 2 hours once per day on days 1 to 4
- Gemcitabine (Gemzar) 800 mg/m2 IV once per day on days 1 & 4
- Vinorelbine (Navelbine) 20 mg/m2 IV once on day 1
Glucocorticoid therapy
- Prednisolone (Millipred) 100 mg PO once per day on days 1 to 4
Supportive therapy
- Mesna (Mesnex) 900 mg/m2 IV three times per day on days 1 to 4, given at 0, 2, 4 hours after ifosfamide (total dose: 10,800 mg/m2)
- Lenograstim (Granocyte) 263 mcg SC once per day on days 7 until at least 3 x 106 CD34+ cells per kg of body weight were collected
Apheresis was performed when the peripheral blood CD34+ cell count exceeded 10 cells/ul. One course
References
- Magagnoli M, Spina M, Balzarotti M, Timofeeva I, Isa L, Michieli M, Capizzuto R, Morenghi E, Castagna L, Tirelli U, Santoro A. IGEV regimen and a fixed dose of lenograstim: an effective mobilization regimen in pretreated Hodgkin's lymphoma patients. Bone Marrow Transplant. 2007 Dec;40(11):1019-25. Epub 2007 Oct 1. link to original article contains dosing details in manuscript PubMed
DexaBEAM & G-CSF
DexaBEAM & G-CSF: Dexamethasone, BiCNU (Carmustine), Etoposide, Ara-C (Cytarabine), Melphalan, Granulocyte Colony Stimulating Factor
Regimen
Study | Dates of enrollment | Evidence |
---|---|---|
Dreyling et al. 2004 | 1996-2004 | Non-randomized part of phase 3 RCT |
Glucocorticoid therapy
- Dexamethasone (Decadron) 8 mg PO three times per day on days 1 to 10
Chemotherapy
- Carmustine (BCNU) 60 mg/m2 IV once on day 2
- Etoposide (Vepesid) 75 mg/m2 IV once per day on days 4 to 7
- Cytarabine (Ara-C) 100 mg/m2 IV twice per day on days 4 to 7
- Melphalan (Alkeran) 20 mg/m2 IV once on day 3
Growth factor therapy
- G-CSF starting on day 11
A minimum of 1 x 106 CD34+ cells/kg are collected. One course
References
- Dreyling M, Lenz G, Hoster E, Van Hoof A, Gisselbrecht C, Schmits R, Metzner B, Truemper L, Reiser M, Steinhauer H, Boiron JM, Boogaerts MA, Aldaoud A, Silingardi V, Kluin-Nelemans HC, Hasford J, Parwaresch R, Unterhalt M, Hiddemann W. Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the European MCL Network. Blood. 2005 Apr 1;105(7):2677-84. Epub 2004 Dec 9. link to original article contains dosing details in manuscript PubMed
Motixafortide & G-CSF
Regimen
Study | Dates of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Crees et al. 2023 (GENESIS) | 2018-01-22 to 2020-10-30 | Phase 3 (E-RT-esc) | G-CSF | Superior primary endpoint |
References
- GENESIS: Crees ZD, Rettig MP, Jayasinghe RG, Stockerl-Goldstein K, Larson SM, Arpad I, Milone GA, Martino M, Stiff P, Sborov D, Pereira D, Micallef I, Moreno-Jiménez G, Mikala G, Coronel MLP, Holtick U, Hiemenz J, Qazilbash MH, Hardy N, Latif T, García-Cadenas I, Vainstein-Haras A, Sorani E, Gliko-Kabir I, Goldstein I, Ickowicz D, Shemesh-Darvish L, Kadosh S, Gao F, Schroeder MA, Vij R, DiPersio JF. Motixafortide and G-CSF to mobilize hematopoietic stem cells for autologous transplantation in multiple myeloma: a randomized phase 3 trial. Nat Med. 2023 Apr;29(4):869-879. Epub 2023 Apr 17. link to original article link to PMC article PubMed NCT03246529
Plerixafor & G-CSF
Regimen
Study | Dates of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
DiPersio et al. 2009 (Study 3101) | 2005-01-18 to 2006-08-20 | Phase 3 (E-esc) | G-CSF | Superior primary endpoint |
DiPersio et al. 2009 (AMD3100-3102) | 2005-02-04 to 2006-07-07 | Phase 3 (E-esc) | G-CSF | Superior primary endpoint |
References
- AMD3100-3102: DiPersio JF, Stadtmauer EA, Nademanee A, Micallef IN, Stiff PJ, Kaufman JL, Maziarz RT, Hosing C, Früehauf S, Horwitz M, Cooper D, Bridger G, Calandra G; 3102 Investigators. Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma. Blood. 2009 Jun 4;113(23):5720-6. Epub 2009 Apr 10. link to original article PubMed NCT00103662
- Study 3101: DiPersio JF, Micallef IN, Stiff PJ, Bolwell BJ, Maziarz RT, Jacobsen E, Nademanee A, McCarty J, Bridger G, Calandra G; 3101 Investigators. Phase III prospective randomized double-blind placebo-controlled trial of plerixafor plus granulocyte colony-stimulating factor compared with placebo plus granulocyte colony-stimulating factor for autologous stem-cell mobilization and transplantation for patients with non-Hodgkin's lymphoma. J Clin Oncol. 2009 Oct 1;27(28):4767-73. Epub 2009 Aug 31. link to original article PubMed NCT00103610